N itroglycerin is one of the most widely used drugs in the treatment of angina. Although there is no doubt about its effectiveness, its mechanism in alleviating angina is still unclear. Two mechanisms have been considered: 1) increase in blood flow to the ischemic myocardium through a direct effect of nitroglycerin on the coronary vessels and 2) a reduction in energy expenditure of ischemic myocardium through an effect of nitroglycerin on systemic vessels. Therefore, results may vary, depending on the experimental preparations studied and the route of administration of the drug. Regarding the direct effect of nitroglycerin on the coronary vessels, Forman et all reported that intracoronary administration of nitroglycerin caused a significant reduction in subendocardial blood flow with a decrease in the subendocardial-to-subepicardial blood flow ratio and depression of subendocardial contractile force in dog hearts with partial coronary artery occlusion. In their experiments, because intracoronary administration of nitroglycerin did not change systemic hemodynamics, these adverse effects of nitroglycerin were considered to be results of direct effect of nitroglycerin on the coronary blood flow. In the clinical study of Ganz and Marcus,2 intracoronary administration of nitroglycerin failed to relieve angina.
Although these studies suggested the possibility that the direct effect of nitroglycerin on the coronary vessels could be deleterious, the effects of nitroglycerin on coronary hemodynamics have not been evaluated in detail. Intracoronary administration of nitroglycerin may decrease coronary perfusion pressure distal to stenosis while dilating coronary vessels. A decrease in coronary perfusion pressure would be expected to decrease myocardial blood flow in subendocardium relative to that in subepicardium.3 Because nitroglycerin dilates extramural coronary arteries predominantly,4'5 it may increase systolic reverse flow by increasing the capacity of extramural coronary arteries to store blood squeezed out of deep myocardial vessels by cardiac contraction. This may decrease the end-systolic diameter of resistance vessels in subendocardium relative to that in subepicardium. Therefore, diastolic resistance to flow may be higher in the subendocardium than in the subepicardium. 6 Other factors, for example, the impaired diastolic property of the left ventricle after stenosis, may also increase diastolic resistance to coronary arterial flow.
If the stenosis is not fixed, nitroglycerin might increase total coronary inflow by dilating the stenotic region, and myocardial ischemia could be relieved. However, if the stenosis is fixed, this relief mechanism is no longer available. In the present study, we focused on the fixed coronary artery stenosis. Recently, we7 investigated the effect of fixed coronary artery stenosis of different severities on phasic velocity waveforms of the intramyocardial coronary artery in dogs. Increasing the severity of the coronary artery stenosis increased systolic reverse flow. We also observed an increase in the systolic reverse flow after intravenous adenosine administration. It should be noted that adenosine dilates mainly smaller coronary arteries, but nitroglycerin dilates relatively larger coronary arteries.
To understand the direct effect of nitroglycerin on coronary hemodynamics, we measured coronary perfusion pressure and the phasic pattern of inflow to the myocardium with coronary artery stenosis before and after intracoronary injection of nitroglycerin in different dogs from those in the experiment by Kimura et al. 7 We especially focused on the change in the degree of systolic reverse flow. To evaluate the effects of nitroglycerin on the transmyocardial distribution of blood flow independent of changes in coronary perfusion pressure, we also measured the transmyocardial blood flow distribution while maintaining coronary pressure at a low constant level.
Methods

Experimental Preparation
Twelve mongrel dogs of either sex weighing 19-38 kg were premedicated with an intramuscular injection of ketamine (200 mg) or 2-3 ml of fentanyl droperidol (Innovar-Vet, Pitman-Moore). The dogs were then anesthetized by intravenous injection of pentobarbital (30 mg/kg). After a cuffed endotracheal tube was inserted and connected to a Harvard respirator pump, the animals were artificially ventilated with 0.5-1.0% halothane and 3 ml/min oxygen at a rate sufficient to maintain arterial oxygen tension within the physiological range. A midline or a left thoracotomy was performed. The heart was exposed and suspended in a (LMCA) was carefully isolated. Heparin (5,000 units i.v. and 3,000 units hourly) was injected intravenously. 
Results
Group 1
Representative tracings of the phasic septal arterial blood flow velocity measured before and after administration of nitroglycerin are shown in Figure 2 . Before administration of nitroglycerin, forward flow into the myocardium was mainly in diastole. In systole, a small amount of reverse flow was present. After administration of nitroglycerin, the diastolic forward flow increased, but the systolic reverse flow was also augmented. These findings were consistent in all the dogs. Figure 3 shows the areas of phasic velocity waveforms before and after administration of nitroglycerin. The systolic reverse velocity area ( Figure 3A) ure 3B). The diastolic velocity area ( Figure 3C ) was increased significantly by the administration of nitroglycerin (p<0.05). There were no significant differences in heart rate before (110.3 +8.5 beats per minute) and after nitroglycerin (108.5±9.6 beats per minute). There were no significant differences in the systolic pressures proximal to the coronary stenosis before (85.3±9.6 mm Hg) and after administration of nitroglycerin (80.3±13.7 mm Hg). The diastolic pressure proximal to the coronary stenosis decreased significantly after administration of nitroglycerin from 61.7±9.8 to 56.2±12.9 mm Hg (p<0.01). The systolic and diastolic pressures distal to the stenosis decreased significantly after nitroglycerin from 66.5± 18.5 to 56.5± 13. were not different before (1.43±1.97 mm Hg) and after nitroglycerin administration (1.07± 1.34 mm Hg, NS). Group 2 The LMCA flow increased significantly after intracoronary administration of nitroglycerin from 64.0±18.8 to 107.7±25.8 ml/min at a coronary perfusion pressure of 40 mm Hg (p<0.001). Figure 5 shows the transmyocardial distribution of coronary flow before and after intracoronary nitroglycerin administration when the perfusion pressure was kept constant at a low level. Before nitroglycerin administration, the myocardial flows were low, especially in the subendocardium. With the administration of nitroglycerin, the subepicardial flow increased significantly from 0.71±0.34 to 1.27±0.51 ml/min/g (p<0.05). On the other hand, the subendocardial flow did not change significantly, being 0.48±0.20 and 0.42±0.30 ml/min/g before and after administration of nitroglycerin, respectively. With the administration of nitroglycerin, the subendocardial-to-subepicardial flow ratio decreased significantly from 0.73±0.19 to 0.32±0.14 (p<0.01). Regarding phasic coronary velocity waveform in the septal artery, nitroglycerin increased the diastolic flow and augmented the systolic reverse flow (Figure 6 ). This was consistent in all the dogs examined and similar to the result shown in Figure  2 . There were no significant differences in To measure the phasic flow pattern in the septal artery, we used the 20-MHz, 80-channel pulsed velocimeter.8 This pulsed Doppler system has been extensively validated.8-10 In steady-flow calibration experiments using a rotating turntable, we compared the velocity output with known water or blood velocities. In pulsatile flow calibration experiments in dogs,8 we compared the femoral arterial blood flow measured by the Doppler system with the blood flow measured by an electromagnetic flowmeter. In both studies, a good linear relation was obtained between the two. However, variability in the angle of incidence of the ultrasonic beam with blood flow in the septal artery could alter the estimate of the blood velocity waveform. Therefore, an effort was made to keep the angle of the probe (400) constant throughout each measurement by the use of a specially designed probe holder. The 80-channel monitor was used to manipulate the holder so that the maximum flow diameter was obtained at the time of peak flow. This ensures that the ultrasound beam passes near the central axial region of the vessel. We used the envelope of the FFT display of blood velocities near the central axial region for the quantitative evaluation of blood velocity waveforms. The envelope may indicate the maximum velocity in the sample volume (the maximum negative velocity in reverse flow) and therefore the maximum velocity within the vessels, because we measured the blood velocity at the central axial region condition and the velocity profile was nearly parabolic (see the left lower panel of Figure 1 ).
Our focus was on coronary hemodynamics under a condition of significant flow effects by nitroglycerin. Therefore, the phasic coronary inflow pattern and intramyocardial blood distribution were measured at peak coronary blood flow, although the vasodilatory effect of nitroglycerin on the epicardial coronary arteries lasted beyond the point at which coronary blood flow returns to the control level. With regard to time, intramyocardial blood flow might differ from that in the epicardial coronary arteries. Furthermore, after the increase of coronary blood flow with nitroglycerin, systemic hemodynamics could start to change even when the nitroglycerin is administrated directly. Because we intended to evaluate the effect of nitroglycerin on intramyocardial blood flow distribution without its influence on systemic hemodynamics, the intramyocardial blood flow was measured in the early phase after intracoronary nitroglycerin administration.
To assess the intramyocardial blood flow distribution, the microsphere technique was used. Although steadystate conditions may be ideal for this technique, it is possible to use radioactive microspheres to assess changes in regional flows such as in reactive hyperemia. Downey et al'6 showed dynamic variation in the transmural distribution of myocardial blood flow during the course of coronary reactive hyperemia. Falsetti et al17 investigated the temporal heterogeneity of myocardial blood flow in anesthetized dogs by using the microsphere technique. In the present study, coronary blood flow increased rapidly after the bolus injection of nitroglycerin into the coronary artery, and this was relatively stable during the peak phase. Therefore, we think that the measurement of myocardial blood flow at peak coronary blood flow is reliable, although it may be a quasi-steady state.
Effect of Intracoronary Nitroglycerin Administration on Phasic Pattern of Intramyocardial Artery Flow and Transmural Distribution of Coronary Flow
In the normal coronary artery, the phasic arterial blood flow waveforms in intramyocardial arteries and in peripheral epicardial arteries exhibit almost exclusively diastolic forward flow, and systolic reverse flow is frequently observed.15 '8,19 With coronary arterial stenosis, the systolic reverse flow increased, whereas diastolic forward flow decreased (Figure 2) . The most plausible explanation of the increased systolic reverse flow after coronary arterial stenosis may be that decreased distal pressure first reduces the back pressure to systolic reverse flow7 and second increases coronary arterial capacitance because of the pressure-dependent capacitance change,20 so that the poststenotic epicardial vessels accommodate more blood from the myocardium during systole. Inertial properties and wave propagation might also contribute to the systolic reverse flow.2'
Intracoronary administration of nitroglycerin augmented the systolic reverse flow, whereas it increased the diastolic flow ( Figure 3A and 3C) . The Regarding the transmural distribution of coronary flow, the intracoronary administration of nitroglycerin failed to increase the subendocardial flow even though a decrease in poststenotic pressure was avoided by maintaining the pressure constant ( Figure 5 ). This may be due to the augmented systolic reverse flow from the subendocardium or a relative increase in the resistance of subendocardial vessels to diastolic flow or a regional steal.27 Origin of the systolic reverse flow from the myocardium to the extramural coronary arteries is not entirely known. However, recent studies on phasic blood flow pattern in the superficial myocardial layer give important information.28,29 In the superficial myocardium, Ashikawa et aV28 measured phasic red cell velocity in the small arterioles by using an intravital microscope system and showed that systolic flow is characterized by sustained forward flow velocity after momentary reverse flow velocity during the isovolumic contraction phase. Therefore, contribution of systolic reverse flow from the superficial layer of the myocardium to the total systolic reverse flow from the myocardium to the extramural coronary arteries is much smaller than that from the deeper layer of the myocardium.
The increased systolic reverse flow from the deep myocardial layer might result in a more pronounced decrease in the diameter of subendocardial vessels than occurs in the normal state, thus resulting in a further increase in vascular resistance. This might also increase stenotic pressure during diastole by an increase in the resistance during diastole, thereby decreasing diastolic flow as explained by the theory of "systolic-diastolic interaction" proposed by Hoffman et al. 6 When the heart rate is high, because the diastolic interval is shortened, this mechanism is enhanced and may explain the failure to relieve pacing-induced angina.2 Inversely, if the heart rate is in the physiological range of about <80 beats per minute, as observed in conscious dogs or in humans, the increase in the diastolic interval may compensate considerably for the early diastolic underperfusion. Decrease in poststenotic pressure caused by intracoronary administration of nitroglycerin might also increase systolic translocation of blood flow from the deep myocardial layer to the superficial layer.30 Therefore, the subepicardial layer may receive blood flow during systole arising from the squeezing of blood out of the subendocardial vessels. We conclude that the increase in systolic intramyocardial translocation of blood from subendocardium to subepicardium and/or relative change in resistance to diastolic flow between subepicardium and subendocardium may result in an increase in the subepicardial flow and the failure to increase the subendocardial flow after nitroglycerin administration.
Clinical Interpretation
Nitroglycerin has been used as one of the most effective drugs for the relief of angina.31 The predominant mechanism may be that nitroglycerin reduces energy expenditure of the ischemic myocardium through the reduction of end-diastolic left ventricular wall tension by decreasing venous return.32 In addition, the increase in myocardial blood flow through dilatation of the coronary arteries5 and coronary collateral channels3334 may contribute to the relief of angina. Nitroglycerin also alters the transmural distribution of myocardial perfusion. It has been reported that intravenous administration of nitroglycerin improved subendocardial underperfusion, i.e., redistribution of blood flow toward the subendocardium in the ischemic heart.35-38 On the other hand, there have been reports that intracoronary administration of nitroglycerin did not improve the pacing-induced angina in humans,2 and that it rather worsened the subendocardial underperfusion and contractile function in ischemic dog hearts.' Thus, the effects of nitroglycerin on the coronary circulation may be altered by the route of administration of the drug.
In this study, we focused on analyzing the direct effect of nitroglycerin on the coronary circulation. As the results show, intracoronary administration of nitroglycerin did not improve subendocardial perfusion in the ischemic hearts. In our experimental preparation, intramyocardial blood flow was measured by injecting radionuclide-labeled microspheres from the LMCA and so does not measure the contribution of any collateral flow from the right coronary artery. Thus, the measured flow distribution might reflect the distribution of anterograde flow, excluding the collateral flow. However, the contribution of collateral flow from the right coronary artery to the left coronary artery seems negligible. Murray et a139 reported the amount of the collateral flow rate from the right coronary artery to the left coronary artery as 0.04±0.01 ml/min/g even when the LMCA was occluded.
When the intramyocardial blood flow was measured, the systolic aortic pressures did not change by the administration of nitroglycerin. At coronary perfusion pressure of 40 mm Hg, left ventricular end-diastolic pressures before (range, 12.5-15.0 mm Hg) and after nitroglycerin administration (range, 10.0-12.5 mm Hg) might contribute to decrease the subendocardial flows in each condition. Decrease in left ventricular end-diastolic pressure tends to increase the subendocardial flow more than the subepicardial flow.40 Because the decrease in the left ventricular end-diastolic pressure by nitroglycerin administration was negligible when the intramyocardial flow was measured, influence of the systemic hemodynamics on the change in the distribution of intramyocardial blood flow may be small. Therefore, the increased systolic reverse flow that was consistently observed after nitroglycerin may be closely related to a reduction of the subendocardial-to-subepicardial flow ratio.
Summary
We measured coronary perfusion pressure, phasic pattern of inflow to the myocardium, and transmyocardial distribution of blood flow to understand the direct effect of nitroglycerin on coronary hemodynamics. Intracoronary administration of nitroglycerin 1) decreased the poststenotic coronary arterial pressure, 2) increased the diastolic velocity but more greatly augmented the systolic reverse velocity, and 3) increased the subepicardial flow but failed to increase the subendocardial flow. These findings may explain the possible deleterious effect of intracoronary administration of nitroglycerin and failure to relieve angina.
